These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 18940985)

  • 1. Prescription drugs, products liability, and preemption of tort litigation.
    DeAngelis CD; Fontanarosa PB
    JAMA; 2008 Oct; 300(16):1939-41. PubMed ID: 18940985
    [No Abstract]   [Full Text] [Related]  

  • 2. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 3. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing postmarketing changes in recommended doses and marketing withdrawals.
    Peck C
    Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 7. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of Wyeth v. Levine on FDA regulation of prescription drugs.
    Ausness RC
    Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MedWatch: the new medical products reporting program.
    Couig MP; Merkatz RB
    Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 12. The preemptive scope of the Medical Device Amendments of 1976.
    Sunshine PH
    Food Drug Law J; 1995; 50(1):191-212. PubMed ID: 10342991
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 15. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
    Struve CT
    Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
    [No Abstract]   [Full Text] [Related]  

  • 16. The demise of drug design litigation: death by federal preemption.
    Twerski AD
    Am Univ Law Rev; 2018; 68(1):281-304. PubMed ID: 30457769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 18. Preemption of the "fraud on the FDA" exception to Michigan's tort immunity statute for drug manufacturers: reconsidering Garcia and Desiano after Levine.
    Murdey J
    Food Drug Law J; 2011; 66(1):85-104, ii-iii. PubMed ID: 24505848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of litigation in defining drug risks.
    Kesselheim AS; Avorn J
    JAMA; 2007 Jan; 297(3):308-11. PubMed ID: 17227983
    [No Abstract]   [Full Text] [Related]  

  • 20. Preemption and malpractice liability.
    Hauser RG
    N Engl J Med; 2009 May; 360(21):2257-8; author reply 2258. PubMed ID: 19458378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.